ENTPD2

Across TCGA pan-cancer cohorts, ENTPD2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ENTPD2 data layer compared with 26 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ENTPD2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ENTPD2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, GBM, and HNSC are the cancer types where ENTPD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.928	0.128	.014	14	view →
GBM	OS	Median	All	0.277	0.459	.014	7	view →
HNSC	OS	Quartile	II,III,IV	0.919	0.547	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ENTPD2–CCRCC (DFS)

Open the CCRCC breakdown →